ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells

S. R. Krig, J. K. Miller, S. Frietze, Laurel A Beckett, R. M. Neve, P. J. Farnham, P. I. Yaswen, Colleen A Sweeney

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Understanding the mechanisms underlying ErbB3 overexpression in breast cancer will facilitate the rational design of therapies to disrupt ErbB2-ErbB3 oncogenic function. Although ErbB3 overexpression is frequently observed in breast cancer, the factors mediating its aberrant expression are poorly understood. In particular, the ErbB3 gene is not significantly amplified, raising the question as to how ErbB3 overexpression is achieved. In this study we showed that the ZNF217 transcription factor, amplified at 20q13 in 20% of breast tumors, regulates ErbB3 expression. Analysis of a panel of human breast cancer cell lines (n50) and primary human breast tumors (n15) showed a strong positive correlation between ZNF217 and ErbB3 expression. Ectopic expression of ZNF217 in human mammary epithelial cells induced ErbB3 expression, whereas ZNF217 silencing in breast cancer cells resulted in decreased ErbB3 expression. Although ZNF217 has previously been linked with transcriptional repression because of its close association with C-terminal-binding protein (CtBP)1/2 repressor complexes, our results show that ZNF217 also activates gene expression. We showed that ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent and that ZNF217 and CtBP1/2 have opposite roles in regulating ErbB3 expression. In addition, we identify ErbB3 as one of the mechanisms by which ZNF217 augments PI-3K/Akt signaling.

Original languageEnglish (US)
Pages (from-to)5500-5510
Number of pages11
JournalOncogene
Volume29
Issue number40
DOIs
StatePublished - Oct 7 2010

Fingerprint

Receptor Protein-Tyrosine Kinases
Oncogenes
Breast Neoplasms
Phosphatidylinositol 3-Kinases
Breast
Transcription Factors
Epithelial Cells
Gene Expression
Cell Line
Genes

Keywords

  • 20q13
  • breast cancer
  • CtBP2
  • ErbB3
  • ZNF217

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. / Krig, S. R.; Miller, J. K.; Frietze, S.; Beckett, Laurel A; Neve, R. M.; Farnham, P. J.; Yaswen, P. I.; Sweeney, Colleen A.

In: Oncogene, Vol. 29, No. 40, 07.10.2010, p. 5500-5510.

Research output: Contribution to journalArticle

Krig, S. R. ; Miller, J. K. ; Frietze, S. ; Beckett, Laurel A ; Neve, R. M. ; Farnham, P. J. ; Yaswen, P. I. ; Sweeney, Colleen A. / ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. In: Oncogene. 2010 ; Vol. 29, No. 40. pp. 5500-5510.
@article{af2c3a521ac145268e0bb32bbb2bbdca,
title = "ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells",
abstract = "Understanding the mechanisms underlying ErbB3 overexpression in breast cancer will facilitate the rational design of therapies to disrupt ErbB2-ErbB3 oncogenic function. Although ErbB3 overexpression is frequently observed in breast cancer, the factors mediating its aberrant expression are poorly understood. In particular, the ErbB3 gene is not significantly amplified, raising the question as to how ErbB3 overexpression is achieved. In this study we showed that the ZNF217 transcription factor, amplified at 20q13 in 20{\%} of breast tumors, regulates ErbB3 expression. Analysis of a panel of human breast cancer cell lines (n50) and primary human breast tumors (n15) showed a strong positive correlation between ZNF217 and ErbB3 expression. Ectopic expression of ZNF217 in human mammary epithelial cells induced ErbB3 expression, whereas ZNF217 silencing in breast cancer cells resulted in decreased ErbB3 expression. Although ZNF217 has previously been linked with transcriptional repression because of its close association with C-terminal-binding protein (CtBP)1/2 repressor complexes, our results show that ZNF217 also activates gene expression. We showed that ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent and that ZNF217 and CtBP1/2 have opposite roles in regulating ErbB3 expression. In addition, we identify ErbB3 as one of the mechanisms by which ZNF217 augments PI-3K/Akt signaling.",
keywords = "20q13, breast cancer, CtBP2, ErbB3, ZNF217",
author = "Krig, {S. R.} and Miller, {J. K.} and S. Frietze and Beckett, {Laurel A} and Neve, {R. M.} and Farnham, {P. J.} and Yaswen, {P. I.} and Sweeney, {Colleen A}",
year = "2010",
month = "10",
day = "7",
doi = "10.1038/onc.2010.289",
language = "English (US)",
volume = "29",
pages = "5500--5510",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "40",

}

TY - JOUR

T1 - ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells

AU - Krig, S. R.

AU - Miller, J. K.

AU - Frietze, S.

AU - Beckett, Laurel A

AU - Neve, R. M.

AU - Farnham, P. J.

AU - Yaswen, P. I.

AU - Sweeney, Colleen A

PY - 2010/10/7

Y1 - 2010/10/7

N2 - Understanding the mechanisms underlying ErbB3 overexpression in breast cancer will facilitate the rational design of therapies to disrupt ErbB2-ErbB3 oncogenic function. Although ErbB3 overexpression is frequently observed in breast cancer, the factors mediating its aberrant expression are poorly understood. In particular, the ErbB3 gene is not significantly amplified, raising the question as to how ErbB3 overexpression is achieved. In this study we showed that the ZNF217 transcription factor, amplified at 20q13 in 20% of breast tumors, regulates ErbB3 expression. Analysis of a panel of human breast cancer cell lines (n50) and primary human breast tumors (n15) showed a strong positive correlation between ZNF217 and ErbB3 expression. Ectopic expression of ZNF217 in human mammary epithelial cells induced ErbB3 expression, whereas ZNF217 silencing in breast cancer cells resulted in decreased ErbB3 expression. Although ZNF217 has previously been linked with transcriptional repression because of its close association with C-terminal-binding protein (CtBP)1/2 repressor complexes, our results show that ZNF217 also activates gene expression. We showed that ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent and that ZNF217 and CtBP1/2 have opposite roles in regulating ErbB3 expression. In addition, we identify ErbB3 as one of the mechanisms by which ZNF217 augments PI-3K/Akt signaling.

AB - Understanding the mechanisms underlying ErbB3 overexpression in breast cancer will facilitate the rational design of therapies to disrupt ErbB2-ErbB3 oncogenic function. Although ErbB3 overexpression is frequently observed in breast cancer, the factors mediating its aberrant expression are poorly understood. In particular, the ErbB3 gene is not significantly amplified, raising the question as to how ErbB3 overexpression is achieved. In this study we showed that the ZNF217 transcription factor, amplified at 20q13 in 20% of breast tumors, regulates ErbB3 expression. Analysis of a panel of human breast cancer cell lines (n50) and primary human breast tumors (n15) showed a strong positive correlation between ZNF217 and ErbB3 expression. Ectopic expression of ZNF217 in human mammary epithelial cells induced ErbB3 expression, whereas ZNF217 silencing in breast cancer cells resulted in decreased ErbB3 expression. Although ZNF217 has previously been linked with transcriptional repression because of its close association with C-terminal-binding protein (CtBP)1/2 repressor complexes, our results show that ZNF217 also activates gene expression. We showed that ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent and that ZNF217 and CtBP1/2 have opposite roles in regulating ErbB3 expression. In addition, we identify ErbB3 as one of the mechanisms by which ZNF217 augments PI-3K/Akt signaling.

KW - 20q13

KW - breast cancer

KW - CtBP2

KW - ErbB3

KW - ZNF217

UR - http://www.scopus.com/inward/record.url?scp=77957784428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957784428&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.289

DO - 10.1038/onc.2010.289

M3 - Article

VL - 29

SP - 5500

EP - 5510

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 40

ER -